carboplatin + pemetrexed + docetaxel + paclitaxel

This is a combination chemotherapy regimen consisting of four cytotoxic agents commonly used in the treatment of various cancers, particularly non-small cell lung cancer (NSCLC). - **Carboplatin** is a platinum-based compound that causes DNA crosslinking and inhibits DNA synthesis and function. - **Pemetrexed** is an antifolate antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication. - **Docetaxel** and **paclitaxel** are taxane derivatives that promote microtubule assembly and stabilization, leading to mitotic arrest and apoptosis. These drugs are often used in various combinations as part of first-line or subsequent therapy for advanced NSCLC and other solid tumors[1][3][5][6]. The combination aims to exploit different mechanisms of action to maximize tumor cell kill but may be limited by cumulative toxicity.